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Abstract  34 
Dogs with babesiosis can present with multiple complications, including acute kidney injury (AKI). The objective of this study was to 35 
characterize AKI in dogs with babesiosis caused by Babesia rossi at presentation and after treatment. Thirty-five client-owned dogs with 36 
B. rossi infection and 10 control dogs were included in this prospective observational study. Blood and urine were collected in Babesia-37 
infected dogs at presentation (T0, n=35), after 24 hours (T24h, n=11), and after 1 month (T1m, n=9). The following urinary kidney injury 38 
biomarkers were assessed: urinary protein to creatinine ratio (UPC), urinary glomerular injury biomarkers (immunoglobulin G (uIgG) and 39 
C-reactive protein (uCRP)), and urinary tubular injury biomarkers (retinol-binding protein (uRBP) and neutrophil gelatinase-associated 40 
lipocalin (uNGAL)). Serum functional renal biomarkers were creatinine (sCr) and symmetric dimethylarginine (sSDMA). Post-mortem 41 
kidney biopsies were analyzed by light and transmission electron microscopy. 42 
At T0, all kidney injury biomarkers were significantly higher in Babesia-infected dogs compared to healthy controls (P<0.001), while 43 
functional renal biomarkers were not significantly different (P>0.05). At T24h, all urinary tubular injury biomarkers and UPC decreased 44 
significantly (P<0.01), while glomerular injury biomarkers did not (P=0.084). At T1m, all urinary kidney injury biomarkers decreased to 45 
values not significantly different from healthy controls (P>0.5). Significant changes in functional renal biomarkers were not seen after 46 
treatment (P>0.05). Dogs with complicated babesiosis had significantly higher glomerular injury biomarkers, UPC, and sSDMA compared 47 
to uncomplicated cases (P<0.05), while all tubular injury biomarkers and sCr were not significantly different (P>0.1). 48 
Dogs with babesiosis caused by B. rossi showed transient kidney injury, which was detected by all kidney injury biomarkers, but remained 49 
undetected by functional biomarkers. All infected dogs, irrespective of disease severity, suffered comparable kidney injury based on 50 




















1. Introduction 69 
Babesia rossi is an intra-erythrocytic protozoan, capable of causing life-threatening disease in infected dogs (Jacobson, 2006). Babesia 70 
species have different tick vectors, with B. rossi in sub-Saharan Africa being transmitted by Haemaphysalis elliptica (and presumably 71 
Haemaphysalis leachi) (Uilenberg et al., 1989; Apanaskevich et al., 2007; Penzhorn et al., 2017). Only the adult life stage of the tick is capable 72 
of transmitting B. rossi (Lewis et al., 1996). Because domestic dogs are not native to sub-Saharan Africa and B. rossi and its tick vector only 73 
occur in this region (Mitchell, 2015), it has been suggested that indigenous African canids are the reservoir hosts of B. rossi (Penzhorn, 74 
2011). Evidence suggests that these indigenous African canids are able to cope with B. rossi infection and become asymptomatic carriers 75 
of this parasite (Penzhorn, 2011). Black-backed jackals were subsequently confirmed to be natural hosts of B. rossi in South Africa 76 
(Penzhorn et al., 2017). After introduction of domestic dogs into sub-Saharan Africa, Haemaphysalis ticks could not only infest their natural 77 
hosts, but also this newly introduced and highly susceptible domestic dog population, in whom the parasite causes disease because they 78 
would have had insufficient time to co-evolve with the B. rossi parasite (Penzhorn, 2011; Mitchell, 2015). In South Africa, severity of this 79 
disease ranges from mild to peracutely fatal (Jacobson and Clark, 1994). Babesia rossi-infected dogs can present with a variety of 80 
complications, including acute kidney injury (AKI), hypotension, hemoconcentration, immune-mediated hemolytic anemia (IMHA), 81 
hepatopathy, hypoglycemia, pancreatitis, cerebral babesiosis, and acute respiratory distress syndrome (ARDS) (Jacobson and Clark, 1994; 82 
Welzl et al., 2001; Keller et al., 2004; Jacobson, 2006; Defauw et al., 2012; Köster et al., 2015). There is accumulating evidence that an 83 
excessive pro-inflammatory host response is a major cause of these B. rossi-associated complications (Welzl et al., 2001; Köster et al., 2015; 84 
Goddard et al., 2016).  85 
Several studies documented that dogs infected with B. rossi often present with mild, non-azotemic manifestations of AKI, while overt acute 86 
renal failure (ARF) is less common (Jacobson and Clark, 1994; Lobetti and Jacobson, 2001; Welzl et al., 2001; Defauw et al., 2012). In a 87 
recently published study, renal azotemia was however diagnosed in 14% of dogs with babesiosis caused by B. rossi, documenting that renal 88 
azotemia is a relatively frequent complication (Defauw et al., 2018). Grading of AKI was introduced by the International Renal Interest 89 
Society (IRIS) in order to emphasize that AKI can vary from mild to severe kidney injury with overt ARF (Cowgill, 2016). Diagnosis of such 90 
milder forms of AKI is difficult, especially in the setting of canine babesiosis. At least 75% of the nephrons must be nonfunctional before 91 
the routine functional renal biomarker serum creatinine (sCr) will increase above the upper limit of the reference interval (Braun et al., 92 
2003; Hokamp and Nabity, 2016). In canine babesiosis, traditional assessment of renal function based on sCr is hampered in several 93 
additional ways. The presence of hemolysis, leading to elevated serum bilirubin and free hemoglobin, can result in interference with the 94 
most commonly used laboratory techniques measuring sCr (Braun et al., 2003; de Scally et al., 2004). Moreover, after experimentally 95 
infecting dogs with Babesia canis, decreasing plasma creatinine concentrations were seen, likely due to an increased plasma volume after 96 
infection (Schetters et al., 2009). Alternatively, a reduced creatinine production in sepsis and in critical illness could also explain this trend 97 
(Doi et al., 2009; Wilson et al., 2012). 98 
Considering these general as well as babesiosis-specific limitations, characterization of babesiosis-induced AKI based on sCr is severely 99 
hampered. More sensitive alternative biomarkers are needed to evaluate AKI in canine babesiosis. Novel urinary biomarkers can detect 100 
kidney injury at an early stage and can quantify and localize injury to a specific origin (i.e., glomerular versus tubular region) (De Loor et 101 
al., 2013; Hokamp and Nabity, 2016). Early recognition of AKI using these sensitive urinary biomarkers allows earlier therapeutic 102 
intervention (De Loor et al., 2013; Hokamp and Nabity, 2016). Symmetric dimethylarginine (SDMA) is a new functional renal biomarker 103 
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that correlates strongly with glomerular filtration rate (GFR) in dogs with chronic kidney disease (CKD) (Nabity et al., 2015). In a recent 104 
study, plasma SDMA was also able to identify dogs with azotemic AKI (Dahlem et al., 2017). In humans, follow-up of renal function after an 105 
episode of AKI is advised at least in high-risk patients, because patients surviving an AKI episode have an independently increased risk to 106 
develop CKD (Coca et al., 2012; Rimes-Stigare et al., 2015; Heung et al., 2016; Vanmassenhove et al., 2018). Kidney injury biomarkers have 107 
the potential to predict renal recovery from AKI in humans (Koraishy and Coca, 2014). 108 
The main objective of this study was to characterize AKI in dogs with babesiosis caused by B. rossi at presentation, during hospitalization, 109 
and at follow-up 1 month after treatment, comparing routine and novel biomarkers of kidney injury and dysfunction. As a secondary aim, 110 
the same biomarkers were compared between dogs with and without complicated babesiosis to determine the effect of complicated 111 
disease on kidney injury and dysfunction.  112 
  113 
2. Materials and methods 114 
2.1. Study population and design 115 
Client-owned dogs presenting with babesiosis to the Onderstepoort Veterinary Academic Hospital (OVAH, University of Pretoria, South 116 
Africa) were prospectively evaluated for inclusion in this observational study between December 2015 and January 2017. Initial diagnosis 117 
of babesiosis was made based on presence of compatible clinical signs and detection of large Babesia species on a stained blood smear. The 118 
causative agent was later confirmed as B. rossi based on polymerase chain reaction (PCR) and reverse line blot (RLB) (Matjila et al., 2008). 119 
During the same period, clinically healthy client-owned control dogs of comparable age and weight presenting to the OVAH for vaccination, 120 
routine sterilization, or blood donation, were also recruited. The study was approved by the Animal Ethics Committee of the University of 121 
Pretoria (protocol numbers V034-14 and V098-15) and informed owner consent was obtained. 122 
In the dogs with babesiosis, a thorough medical history, physical examination, complete blood count, biochemistry profile (sCr, serum urea, 123 
glucose, total protein, albumin, globulin, alanine aminotransferase, alkaline phosphatase, total bilirubin, and phosphate) and a complete 124 
routine urinalysis (including urinary protein to creatinine ratio (UPC) and aerobic bacterial culture) was performed at presentation (T0), 125 
also to exclude concurrent diseases. Blood pressure was measured in all dogs with babesiosis using oscillometry. Blood and urine samples 126 
were collected before any therapy, especially fluid therapy, was initiated. Control dogs were considered healthy based on the absence of 127 
clinically relevant abnormalities in the medical history, physical examination, complete blood count, biochemistry profile, and a complete 128 
routine urinalysis (including a UPC <0.5). Urine was collected by cystocentesis in all dogs. 129 
In both groups, dogs with a urinary tract infection (UTI) at T0 were excluded based on bacterial growth detection in urine within 3 days of 130 
incubation. Dogs with suspected pre-existing CKD were excluded as best as possible based on a thorough history and physical examination. 131 
Dogs were also excluded if wounds or trauma were evident, if concurrent neoplastic, inflammatory, cardiac disease, or other infections 132 
were diagnosed, or if they were known to have been treated with anti-inflammatory medication within 4 weeks prior to presentation. 133 
PCR/RLB batch analysis for babesiosis and ehrlichiosis was performed in both groups. Dogs with babesiosis were included only after 134 
confirmation of B. rossi infection and after exclusion of Babesia vogeli and/or concurrent Ehrlichia canis infection. Control dogs that tested 135 
positive for any Babesia species or E. canis were excluded. 136 
In dogs with babesiosis, follow-up blood and urine samples were obtained 24 hours after presentation (T24h) and 1 month after treatment 137 
(T1m) whenever possible. Follow-up samples at T24h were only collected in dogs that were hospitalized because of disease severity. At T24h, 138 
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sCr was measured and a complete urinalysis was performed. A complete blood count, biochemistry profile and complete urinalysis as well 139 
as PCR/RLB for babesiosis and ehrlichiosis was repeated at T1m. 140 
All infected dogs received antibabesial treatment with diminazene aceturate (Berenil RTU, Intervet, Kempton Park, South Africa) at 3.5 141 
mg/kg, and standard supportive care such as packed red blood cells and intravenous fluid therapy as needed. Any complications were 142 
treated as needed by the attending clinician. Dogs were diagnosed with complicated babesiosis when at least one of the following 143 
complications were diagnosed either at presentation or during hospitalization. These criteria were based on previous publications defining 144 
complicated babesiosis and severe falciparum malaria (Jacobson and Clark, 1994; Jacobson, 2006; WHO, 2014). Dogs were considered to 145 
be collapsed at presentation when they were unable to walk unaided. Hypotension was defined as a mean arterial pressure <80 mmHg. 146 
Severe anemia was diagnosed when the hematocrit was <0.15. Hemoconcentration was defined as a hematocrit >0.37 in combination with 147 
signs of intravascular hemolysis (macroscopic hemoglobinuria and/or hemoglobinemia). Secondary IMHA was diagnosed based on a 148 
positive in-saline agglutination test. Diagnosis and grading of AKI was based on IRIS criteria (Cowgill, 2016). Grade I AKI was defined as a 149 
progressive increase in sCr (of at least 26.4 µmol/L) within the non-azotemic range and within 48 h. Hypoglycemia was diagnosed when 150 
blood glucose was <3.3 mmol/L. Jaundice was diagnosed when severe hyperbilirubinemia was present (total bilirubin >50 µmol/L). 151 
Cerebral babesiosis was defined as presence of neurological signs not attributable to another cause, such as hypoglycemia. Clinical 152 
diagnosis of ARDS was based on presence of dyspnea and variably on arterial blood gas analysis, radiological evidence of pulmonary edema, 153 
and exclusion of other causes of pulmonary edema. Outcome categories were short-term survival (i.e., survival until discharge) or 154 
death/euthanasia due to poor prognosis (as deemed by the attending clinician), and long-term survival (i.e., survival based on telephone 155 
contact with owners 4-5 weeks after presentation). 156 
 157 
2.2. Sample handling and laboratory analyses 158 
Automated analyzers were used for complete blood count (ADVIA 2120, Siemens, Munich, Germany) and serum biochemistry analysis 159 
(Cobas Integra 400 plus, Roche Diagnostics, Mannheim, Germany). Serum creatinine was determined using a modified Jaffe method. 160 
A complete urinalysis, including dipstick (Combur 9 Test®, Roche Diagnostics, Germany), urine specific gravity (USG), microscopic 161 
sediment analysis within 60 minutes, UPC, and aerobic bacterial culture, was performed. After urine collection, 0.5 ml of uncentrifuged 162 
urine was submitted for aerobic bacterial culture. After centrifugation of remaining urine (3 minutes at 447 x g), the supernatant was used 163 
for dipstick analysis, measurement of USG by refractometry (Atago MASTER-SUR/NM, Atago Co., Tokyo, Japan), and measurement of UPC. 164 
Remaining supernatant was divided into aliquots of 0.5-1 ml, followed by storage at -80 °C. Remaining plasma and serum of all samples 165 
were also stored at -80 °C. PCR/RLB batch analysis was performed on stored packed blood cell pellets. Urine osmolality (uOsmol) was 166 
measured as a batch by freezing point depression within 10 m after collection (Micro-Osmometer Autocal Type 13/13DR, Roebling, Berlin, 167 
Germany). Osmolality of a calibration standard solution was measured in triplicate every day before sample analysis. All samples were 168 
measured in duplicate or triplicate, and the mean uOsmol and intra-assay coefficient of variation were calculated. Calculated mean uOsmol 169 
values from an individual dog at one time point were used, since individual coefficient of variation values were all <1% and global intra-170 
assay coefficient of variation was 0.16%. Frozen samples were transported on dry ice from South Africa to Belgium for renal biomarker 171 
analysis. Upon arrival in Belgium, samples were still frozen and stored at -72 °C until biomarker analysis. 172 
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Kidney injury biomarkers, measured by commercial immunoassays at T0, T24h, and T1m, included urinary immunoglobulin G (uIgG), urinary 173 
C-reactive protein (uCRP), urinary retinol-binding protein (uRBP), urinary and plasma neutrophil gelatinase-associated lipocalin (uNGAL 174 
and pNGAL). Measurement of uIgG and uCRP was performed with canine sandwich enzyme-linked immunosorbent assay (ELISA) kits 175 
(Immunology Consultants Laboratory, Newberg, USA), while uRBP was measured with a human sandwich ELISA kit (Immunology 176 
Consultants Laboratory, Newberg, USA). Validation of the IgG, CRP, and RBP assays for use in canine urine was previously performed in 177 
our laboratory (Maddens et al., 2010). Measurement of uNGAL and pNGAL was performed with a validated canine sandwich ELISA kit 178 
(BioPorto Diagnostics A/S, Hellerup, Denmark). Quantification of uIgG, uCRP, uRBP, uNGAL and pNGAL by immunoassays was performed 179 
as described (Defauw et al., 2012). Finally, urinary biomarker concentrations were normalized to urinary creatinine concentrations (/uCr). 180 
By dividing absolute uNGAL concentrations by pNGAL concentrations, the u/pNGAL concentration ratio was calculated (Uttenthal et al., 181 
2012). The purpose of uNGAL to pNGAL normalization was to aid in the differentiation between kidney injury and non-renal increases of 182 
NGAL. All analyses of kidney injury biomarkers were performed within 6 months of sample collection, except 1 sample for uIgG and 4 183 
samples for uRBP that required re-analysis with another dilution. Serum SDMA (IDEXX SDMATM Test) was measured as a novel functional 184 
renal biomarker at T0, T24h, and T1m. Serum samples were transported on dry ice to a reference diagnostic laboratory (IDEXX Laboratories, 185 
Inc., Ludwigsburg, Germany) for batch analysis. All sSDMA samples were analyzed within 24 months after collection. 186 
 187 
2.3. Renal samples, light microscopy, and transmission electron microscopy 188 
Post-mortem kidney biopsies were obtained whenever possible. Tissue samples were fixed in 10% buffered formalin for light microscopy 189 
(LM), and in 3% buffered glutaraldehyde for transmission electron microscopy (TEM). Samples were processed into paraffin wax blocks 190 
for LM and resin-embedded blocks for TEM. For LM, sections were stained with hematoxylin and eosin, periodic acid-Schiff (PAS), Masson’s 191 
trichrome, and periodic acid methenamine silver, according to standard procedures (Aresu et al., 2017). All sections for LM and TEM were 192 
examined by a board-certified veterinary pathologist (LA). 193 
 194 
2.4. Statistical analysis 195 
As the normal distribution assumption did not hold for some of the biomarkers, Mann-Whitney U tests were used to compare renal 196 
biomarkers between dogs with and without babesiosis, and between dogs with complicated and uncomplicated babesiosis. Renal 197 
biomarkers in B. rossi-infected dogs were compared between T0, T24h, and T1m using Wilcoxon signed-rank tests for paired samples. P values 198 
<0.05 were considered significant. Data were visualized through box plots. All analyses were performed using R (R version 3.3.2 Copyright 199 
© 2016, The R Foundation for Statistical Computing). 200 
 201 
3. Results 202 
3.1. Study population and clinicopathological findings 203 
Forty-three dogs with babesiosis were evaluated for inclusion. Eight dogs were excluded for the following reasons: based on PCR/RLB 204 
analysis, 4 dogs tested positive for E. canis, one dog was infected with B. vogeli, and one dog was repetitively negative by PCR/RLB for 205 
Babesia species; 2 dogs had a UTI at presentation. For practical reasons, aerobic bacterial culture was not performed in urine of 3 dogs. 206 
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These 3 dogs were included, because a UTI was considered unlikely, based on the absence of compatible clinical signs and of pyuria and 207 
bacteriuria on sediment analysis. 208 
Finally, 35 of the 43 dogs with B. rossi infection were included. Ten dogs served as healthy controls. There was no significant age difference 209 
between dogs with babesiosis (median, 2.5 years; range, 2 months to 12.5 years) and controls (2 years; 4 months to 9.5 years) (P=0.47). 210 
Body weight also did not differ significantly between Babesia-infected dogs (22 kg; 2.1-48 kg) and controls (28.45 kg; 4.9-61 kg) (P=0.20). 211 
In the babesiosis group, there were 9 mixed breed dogs, 2 American pit bull terrier, 2 Boerboel, 2 Jack Russell terrier, 2 Labrador retriever, 212 
2 Pekingese, 2 Weimaraner, and a single dog from other breeds. The controls consisted of 3 German shepherd, 2 mixed breed dogs, and a 213 
single dog from other breeds. Hematology and biochemistry results of both groups are summarized in Table 1. 214 
In the dogs with babesiosis, urine ranged from clear to very turbid and urine color ranged from yellow to dark brown. In the urinary 215 
dipstick analysis of Babesia-infected dogs, pH ranged from 5 to 8, proteinuria from 1+ to 3+, bilirubinuria from negative to 3+, 216 
hemoglobinuria from negative to 4+ (4+ in 30/35 dogs), while glucose and ketones were always negative. Bilirubin crystalluria was present 217 
in 9 dogs with babesiosis. Rare to large amounts of granular casts were seen in 23 Babesia-infected dogs, while rare hyaline casts were 218 
seen in 5 Babesia-infected dogs. Microscopic hematuria (i.e., >5 red blood cells/high power field) was seen in 6 Babesia-infected dogs, while 219 
pyuria (i.e., >5 white blood cells/high power field) was absent in all dogs. 220 
 221 
3.2. AKI biomarkers at T0 222 
In Table 2, results of routine renal biomarkers (sCr, serum urea, USG, uOsmol, and UPC) at T0 are compared between healthy controls and 223 
dogs with babesiosis. In Fig. 1 and Table 3, results of kidney injury biomarkers (uIgG/uCr, uCRP/uCr, uRBP/uCr, uNGAL/uCr, pNGAL, 224 
u/pNGAL) and sSDMA at T0 are presented and compared between both groups. All kidney injury biomarkers, including UPC, were 225 
significantly higher in Babesia-infected dogs compared to healthy controls, while sCr, serum urea, USG, uOsmol, and sSDMA did not 226 
significantly differ between both groups at T0. However, when healthy controls were compared with the subgroup of dogs with 227 
uncomplicated babesiosis, sCr was significantly lower in the dogs with uncomplicated disease (P=0.009). 228 
Based on the reference interval (0–14 µg/dL for adult dogs, 0–16 µg/dL for dogs up to 12 m), 3/10 healthy dogs (30%) and 16/35 dogs 229 
with babesiosis (46%) showed increased sSDMA concentrations. On physical examination, 7/35 dogs with babesiosis had clinical signs of 230 
dehydration, of which 4 had increased sSDMA concentrations. 231 
 232 
3.3. Follow-up at T24h and T1m 233 
Twenty-four of the 35 dogs with babesiosis were hospitalized. At T24h, follow-up blood and urine samples were collected in 11 dogs with 234 
babesiosis, and follow-up samples were available from 9 Babesia-treated dogs at T1m. Seven of these dogs had follow-up samples collected 235 
at both T24h and T1m. Because of a UTI, one dog at T24h and 2 dogs at T1m were excluded from urinary kidney injury biomarker analyses. One 236 
of the 9 dogs had a faintly positive PCR/RLB test for a Babesia species at T1m. With exception of sSDMA, which was borderline increased 237 
(15 µg/dL), all renal biomarkers in this dog were normalized at T1m. Short-term survival was 89% (31/35 dogs). Two dogs died 238 
spontaneously within 8 hours after admission, while 2 dogs were euthanized during hospitalization due to poor prognosis. As for long-239 
term survival, all dogs discharged from the hospital survived, but 2 dogs were lost to follow-up. 240 
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In Table 2, routine renal biomarkers results are compared between T0, T24h, and T1m. In Fig. 1 and Table 3, results of kidney injury 241 
biomarkers and sSDMA are compared between T0, T24h, and T1m. Results of biomarker comparison between healthy controls and Babesia-242 
treated dogs at T1m are also shown in Fig. 1, Tables 2 and 3. 243 
At T24h, UPC, uRBP/uCr, uNGAL/uCr, and u/pNGAL decreased significantly (Tables 2 and 3, Fig. 1). At T1m, decreases were significant for 244 
USG and all urinary kidney injury biomarkers (Tables 2 and 3, Fig.1). Significant changes in sCr, sSDMA, pNGAL, and uOsmol were not seen 245 
during follow-up at T24h and T1m. At T1m, all renal biomarkers had values not significantly different from the healthy controls, except for 246 
pNGAL which was still significantly higher in the Babesia-treated dogs. At T24h, 6/11 dogs with babesiosis (55%) had increased sSDMA 247 
concentrations, while at T1m 2/9 dogs with babesiosis (22%) had a borderline increased sSDMA (15 µg/dL). 248 
 249 
3.4. Uncomplicated and complicated babesiosis at presentation and during hospitalization 250 
Ten dogs were diagnosed with uncomplicated babesiosis, while at least one complication occurred in each of the remaining 25 dogs. At T0, 251 
7 dogs were collapsed, 4 dogs were hypotensive, 9 dogs were severely anemic, 3 dogs were diagnosed with hemoconcentration, while 4 252 
dogs presented with secondary IMHA. Based on sCr, 3 dogs were mildly azotemic and diagnosed with AKI grade II. Two of these dogs had 253 
prerenal azotemia based on presence of concentrated urine (USG ≥1.030; uOsmol ≥1110 mOsmol/kg). The other dog was diagnosed with 254 
renal azotemia (USG 1.018; uOsmol 430 mOsmol/kg). Four dogs were hypoglycemic, while jaundice was diagnosed in 5 dogs. Cerebral 255 
babesiosis was diagnosed in 2 dogs. 256 
At T24h, sCr was available in 13 dogs and 5 additional cases of AKI were diagnosed (3 and 2 dogs with AKI grade I and II, respectively). 257 
Finally, one dog was diagnosed with ARDS during hospitalization. Of the 9 dogs with follow-up available at T1m, 2 dogs were presented with 258 
AKI grade II at T0, while 2 dogs developed AKI grade I and one dog AKI grade II during hospitalization. In these 5 dogs diagnosed with AKI 259 
at T0 or T24h, no evidence of kidney injury or dysfunction was detected at T1m, except for one dog with a borderline increased sSDMA (15 260 
µg/dL). 261 
 262 
3.5. AKI biomarkers in uncomplicated and complicated babesiosis at T0 263 
In Table 4, results of routine renal biomarkers, kidney injury biomarkers, and sSDMA at T0 are compared between the subgroups of dogs 264 
with uncomplicated and complicated disease. Dogs with complicated babesiosis had significantly higher uIgG/uCr, uCRP/uCr, UPC, serum 265 
urea, and sSDMA, while uRBP/uCr, uNGAL/uCr, pNGAL, u/pNGAL, USG, uOsmol, and sCr did not differ significantly between groups. 266 
Increased sSDMA concentrations were seen in 14/25 dogs with complicated disease (56%), while 2/10 dogs with uncomplicated 267 
babesiosis (20%) had increased sSDMA concentrations. Finally, sSDMA was increased in 2/3 dogs with an elevated sCr at T0. 268 
 269 
3.6. Histological and ultrastructural renal findings in dogs with complicated babesiosis 270 
Within 6 hours after spontaneous death, kidney samples were obtained from 2 dogs with complicated babesiosis. Dog 1 was a 2-month-271 
old male intact Irish wolfhound, presenting with peracute cerebral babesiosis. The first clinical signs (lethargy and vomiting) were noticed 272 
a couple of hours before presentation. Serum creatinine was 34 µmol/L, sSDMA was 12 µg/dL, and UPC was 2.76. Urine sediment showed 273 
mild microscopic hematuria and absence of casts. Kidney injury biomarkers were as followed: uIgG/uCr: 126.03 mg/g, uCRP/uCr: 0.21 274 
mg/g, uRBP/uCr: 0.26 mg/g, uNGAL/uCr: 77.44 µg/g, pNGAL: 8.57 ng/mL, u/pNGAL: 19.98. A moderate increase of mesangial matrix was 275 
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seen at glomerular level, but the most significant lesions were evident at tubular level. Multifocally, tubules were necrotic and intratubular 276 
protein casts (PAS-positive) were identified. Many tubules showed degenerating epithelial cells, characterized by cellular swelling and 277 
cytoplasmic rarefaction. Focal tubular epithelial cells showed loss of brush border. The histological diagnosis was compatible with a 278 
multifocal, moderate acute tubular necrosis (ATN) and degeneration further confirmed by TEM. 279 
Dog 2 was a 10-year-old male intact mixed breed dog, presenting with a 4-day history of anorexia and lethargy. The dog was collapsed, 280 
hypotensive, and severely hypoglycemic at presentation. Serum creatinine was 101 µmol/L, sSDMA was 20 µg/dL, and UPC was 7.73. Urine 281 
was dark brown and turbid, sediment showed a large amount of granular casts. Kidney injury biomarkers were as followed: uIgG/uCr: 282 
1708.90 mg/g, uCRP/uCr: 10.55 mg/g, uRBP/uCr: 7.71 mg/g, uNGAL/uCr: 2354.03 µg/g, pNGAL: 121.77 ng/mL, u/pNGAL: 34.02. A 283 
moderate increase of mesangial matrix was observed, but no other glomerular or tubular alterations were evident both at LM and TEM. 284 
 285 
4. Discussion 286 
In this population of dogs with babesiosis caused by B. rossi, our selected kidney injury biomarkers were all able to detect kidney injury at 287 
an earlier stage compared to both serum functional renal biomarkers (i.e., sCr and sSDMA). Earlier recognition of AKI could ultimately lead 288 
to an improved outcome by allowing prompt therapeutic interventions and appropriate monitoring. Moreover, there was no evidence of 289 
active ongoing kidney injury at T1m, suggesting a transient nature of kidney injury in most dogs after successful treatment. All infected dogs, 290 
irrespective of disease severity (uncomplicated versus complicated babesiosis), suffered from comparable kidney injury based on tubular 291 
injury biomarker concentrations. However, sSDMA was significantly higher in dogs with complicated babesiosis, suggesting that renal 292 
function should be monitored more closely in this subgroup of critically ill dogs. 293 
All kidney injury biomarkers were significantly higher in Babesia-infected dogs compared to healthy controls, while neither of the 294 
functional renal biomarkers differed significantly. Increased urinary concentrations of glomerular and tubular injury biomarkers (i.e., uIgG, 295 
uCRP and uRBP) in dogs with uncomplicated B. rossi infection have been documented in a previous study from our group (Defauw et al., 296 
2012). Similar findings were observed in 2 recently published papers on B. canis infections in Europe, where glomerular and tubular injury 297 
were also detected based on increased urinary kidney injury biomarkers (Winiarczyk et al., 2017; Kuleš et al., 2018). Another study 298 
involving B. rossi demonstrated, based on urine sediment analysis, UPC and urinary enzyme concentrations, that milder manifestations of 299 
kidney injury are much more common than overt ARF (Lobetti and Jacobson, 2001). Based on these studies, B. rossi-induced AKI manifests 300 
itself primarily by kidney injury rather than by loss of function. However, an important limitation is that the functional renal biomarkers 301 
used in all these studies are either insensitive (sCr) or not fully validated for use in canine AKI (sSDMA) (Hokamp and Nabity, 2016; Dahlem 302 
et al., 2017). Indeed, sSDMA correlates well to GFR in dogs with CKD (Nabity et al., 2015), but the relation between sSDMA and GFR in dogs 303 
with AKI remains unknown (Dahlem et al., 2017). A recent study demonstrated that plasma SDMA was an excellent biomarker to identify 304 
azotemic AKI in dogs, but dogs with non-azotemic AKI grade I were not evaluated (Dahlem et al., 2017). 305 
In the current study NGAL was used for the first time in Babesia-infected dogs as a sensitive biomarker of tubular injury (Segev et al., 2013; 306 
Nabity et al., 2015). In a previous study, uNGAL was also increased in dogs with AKI Grade I, showing its potential as a sensitive biomarker 307 
of milder forms of AKI (Segev et al., 2013). However, in human medicine (Mårtensson and Bellomo, 2014) and more recently also in 308 
veterinary medicine (Cortellini et al., 2015; Cobrin et al., 2016), the specificity of NGAL for AKI has been questioned. It is important to 309 
realize that competition for tubular reabsorption between NGAL and other filtered proteins could result in increased uNGAL and u/pNGAL 310 
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ratio as well, independent of the presence of tubular injury (Nejat et al., 2012). During systemic inflammation, pNGAL and uNGAL can also 311 
increase due to increased synthesis from non-renal tissues and increased release from circulating neutrophils (Mårtensson and Bellomo, 312 
2014). Because both systemic and urinary NGAL concentrations were measured in this study, the impact of systemically originating NGAL 313 
in canine babesiosis can be assessed to a certain extent. The u/pNGAL ratio was also calculated in the current study to aid in the 314 
differentiation between kidney injury and non-renal causes of increased uNGAL, because relatively higher concentrations of uNGAL 315 
compared to pNGAL are expected during kidney injury (Uttenthal et al., 2012). To the authors’ knowledge, this ratio has never been used 316 
in dogs before, but it has been applied in several other species, including humans (Bagshaw et al., 2010; Nielsen et al., 2010; Kaucsár et al., 317 
2016). The u/pNGAL ratio does however not correct for variations in the urinary flow rate. When NGAL concentrations in the current study 318 
were compared to NGAL concentrations reported in a study with septic dogs (Cortellini et al., 2015), the median systemic NGAL 319 
concentration was 5-6 times higher in dogs with bacterial sepsis compared to dogs with babesiosis, while the median uNGAL concentration 320 
was very similar in both studies. The relative impact of systemically orginating NGAL on the total uNGAL concentration therefore seems 321 
less pronounced in dogs with babesiosis, which is suggestive of more kidney injury-specific increases of uNGAL in dogs with babesiosis 322 
compared to septic dogs. The highly increased u/pNGAL ratio at T0 is also supportive of kidney injury-specific increases of uNGAL in B. 323 
rossi-infected dogs. Why NGAL appears to be more specific for kidney injury in the current study compared to other studies (Cortellini et 324 
al., 2015; Cobrin et al., 2016), may be explained by the fact that all dogs in our study were infected with the same organism which causes a 325 
disease in which neutrophilia is uncommon (Scheepers et al., 2011), thus reducing the impact of NGAL originating from circulating 326 
neutrophils (Mårtensson and Bellomo, 2014).  327 
Several studies in humans demonstrated an increased risk for CKD and long-term mortality after an AKI episode (Coca et al., 2009; Heung 328 
et al., 2016; Vanmassenhove et al., 2018). This increased risk was documented even after milder forms of AKI with apparent fast recovery 329 
(Coca et al., 2009; Heung et al., 2016). Using specific biomarkers to detect active ongoing kidney injury might help to predict which dogs 330 
are at risk of developing CKD (Cowgill et al., 2016). Therefore, the concentration of renal biomarkers was followed over time in a subset of 331 
B. rossi-infected dogs to assess the reversibility of kidney injury and dysfunction. 332 
At T24h, all urinary biomarkers of tubular injury (i.e., uRBP and uNGAL) and u/pNGAL decreased significantly more rapidly compared to 333 
those of glomerular injury (i.e., uIgG and uCRP), whose decreases only became significant by T1m. This finding indicates that ongoing tubular 334 
injury quickly abates, while uIgG and uCRP concentrations take longer to decrease likely due to ongoing glomerular injury and persistently 335 
increased serum concentrations of these proteins. Several studies demonstrated increased serum CRP concentrations in canine babesiosis, 336 
and in 2 of these only a mild decrease was seen after 24 hours (Matijatko et al., 2007; Köster et al., 2009). Even though glomerular barrier 337 
injury must occur before uIgG and uCRP can be detected (D'Amico and Bazzi, 2003), the extent to which variations in their serum 338 
concentrations influence these urinary concentrations is unknown. With exception of pNGAL, all kidney injury biomarkers were not 339 
significantly different at T1m compared to healthy controls, suggesting that there was no evidence of active ongoing kidney injury in these 340 
dogs 1 month after Babesia-induced AKI. This finding argues for a transient nature of the kidney insult caused by acute B. rossi infections. 341 
The reason for increased pNGAL concentrations at T1m is unclear. It is very unlikely that tubular injury was still ongoing, considering the 342 
low uNGAL concentrations at that time. Therefore, non-renal causes of increased pNGAL are likely, such as the presence of an unrelated 343 
inflammatory condition. Based on sCr and sSDMA, there was no evidence of decreased renal function at T1m. However, sensitivity for 344 
decreases in GFR is limited for both of these functional biomarkers, especially for sCr (Hokamp and Nabity, 2016). Moreover, 2 dogs had a 345 
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borderline increased sSDMA at T1m (15 µg/dL). One of these dogs had a sCr of 110 µmol/L and highly concentrated urine, but the other dog 346 
(sCr of 93 µmol/L) had a relatively low urinary concentration at T1m (USG 1.022; uOsmol 776 mOsmol/kg). Based on the normalization of 347 
all kidney injury biomarkers, there was no evidence of active kidney injury in these 2 dogs at T1m. Whether the dog with relatively low 348 
urinary concentration had early-stage CKD, is uncertain. Although there was no evidence of active kidney injury based on the investigated 349 
kidney injury biomarkers in this small number of dogs included at T1m, a long-term follow-up study, including a larger numbers dogs 350 
followed over a longer time period, would be necessary to fully clarify if there is an increased risk for the development of CKD related to 351 
early-life Babesia-induced AKI. 352 
In dogs with complicated disease, both of the glomerular injury biomarkers were significantly higher, while none of the tubular injury 353 
biomarkers differed significantly between uncomplicated and complicated cases. More severe glomerular injury and/or higher systemic 354 
concentrations of IgG and CRP in complicated cases could explain these findings. Significantly higher sSDMA concentrations in complicated 355 
cases could be explained by a decreased GFR caused by renal hypoperfusion and/or intrinsic AKI (Choi et al., 2017; Dahlem et al., 2017). 356 
Renal hypoperfusion, for example due to dehydration, is unlikely to be the main reason of higher sSDMA concentrations in most 357 
complicated cases when urinary concentrating ability is taken into account, as a higher uOsmol would be expected in that situation. 358 
However, uOsmol was close to being significantly lower in dogs with complicated babesiosis. Overall, these findings confirm that all dogs 359 
with babesiosis caused by B. rossi, irrespective of disease severity, suffer kidney injury based on the urinary biomarker results, while 360 
sSDMA and uOsmol concentrations suggest that the infection also induces significant loss of renal function in many dogs with complicated 361 
babesiosis. 362 
Moderate to severe ATN and degeneration, without significant morphological lesions at glomerular level, were identified in dog 1. These 363 
findings are consistent with the sparse literature available on renal histological changes in canine babesiosis caused by large species which 364 
document mainly tubular lesions (Maegraith et al., 1957; Hildebrandt, 1981; Irwin and Hutchinson, 1991; Máthé et al., 2007). Unexpectedly, 365 
mild morphological changes were found in dog 2, whose clinical presentation and presence of highly elevated kidney injury biomarkers 366 
were suggestive of clinically significant AKI. Animals in experimental studies and people with hypoxic and/or septic AKI also often lack 367 
histological ATN, either because of its absence or because of mild, focally distributed lesions (Langenberg et al., 2008; Heyman et al., 2010; 368 
Takasu et al., 2013). It is well documented in human nephropathology that renal tissue injury is often limited and focal when a clinical 369 
diagnosis of AKI/ATN is made (Heyman et al., 2010). Consequently, kidney injury biomarkers could lack accuracy for diagnosing 370 
histological ATN, which has already been documented in humans (Moledina et al., 2017). Considering only 2 dogs had histological 371 
evaluations performed in this study, additional research is necessary to clarify the link between kidney injury biomarkers and histological 372 
findings. 373 
Considering that degeneration and necrosis of the tubular cells are amongst the most common histological changes seen in kidneys of dogs 374 
infected with large Babesia spp. (Maegraith et al., 1957; Irwin and Hutchinson, 1991; Máthé et al., 2007), higher concentrations of tubular 375 
injury biomarkers were anticipated in dogs with complicated disease. Rather unexpectedly, these biomarkers did not differ significantly 376 
between uncomplicated and complicated cases, while the functional renal biomarker sSDMA was significantly higher in complicated cases. 377 
These findings could potentially be explained by concurrent presence of multiple mechanisms leading to Babesia-induced AKI that variably 378 
influenced biomarker concentrations. Increasing severity of AKI, as defined by IRIS AKI grading, was also not reflected by increasing uNGAL 379 
concentrations in a previous study in dogs (Segev et al., 2013). Other potential explanations for these unexpected findings include a 380 
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possible influence of the criteria defining uncomplicated versus complicated disease, and the limited information available for sSDMA as a 381 
functional renal biomarker in canine AKI (Dahlem et al., 2017). The presence of a type II error to detect differences in tubular injury 382 
biomarker concentrations between uncomplicated and complicated cases can also not be excluded. 383 
For practical reasons, follow-up at T24h and T1m was lacking for many cases. Some complications such as AKI grade I, as well as statistically 384 
significant differences might have been missed by this low number of dogs with follow-up. However, confirmation of full clinical recovery 385 
was obtained by telephone contact for all discharged dogs. Only dogs hospitalized because of disease severity had follow-up samples at 386 
T24h, leading to a sampling bias. Additional AKI diagnoses were made in 5/13 dogs with sCr follow-up at T24h, which is likely to be an 387 
overestimation due to this bias. 388 
 389 
5. Conclusions 390 
Dogs with babesiosis caused by B. rossi showed transient kidney injury, which was detected by all kidney injury biomarkers, yet remained 391 
undetected by routine and novel functional biomarkers. Nonetheless, our results also suggest that dogs with complicated babesiosis are 392 
more likely to present with significant loss of renal function. Therefore, adequate supportive therapy and monitoring of renal function 393 
during and after treatment is strongly advised for all dogs with babesiosis caused by B. rossi, even when no evidence of AKI is present based 394 
on routine sCr measurements. 395 
 396 
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Table 1  554 
Clinicopathological findings in 10 healthy control dogs and 35 dogs with babesiosis at presentation. All variables are expressed as median 555 
(range). 556 
Variable (unit)    RI  H   B 557 
Hematocrit (L/L)    0.37–0.55  0.47 (0.41–0.57)  0.23 (0.06–0.63) 558 
WBC (x 109 /L)    6–15  8.75 (7.01–12.4)  6.75 (1.93–22.15) 559 
Segmented neutrophil count (x 109 /L)  3–11.5  5.77 (2.94–8.93)  4.32 (1.17–15.28) 560 
Band neutrophil count (x 109 /L)  0–0.5  0 (0–0.12)  0.16 (0–2.13) 561 
Platelet count (x 109 /L)   200–500  281 (142–467)  11 (0–166) 562 
Total serum protein (g/L)   56–73  55 (48–68)  56 (42–81) 563 
Serum albumin (g/L)   28–41  35 (33–38)  25 (14–36) 564 
sCr (µmol/L)    59–109  82 (47–104)  63 (25–132)  565 
Serum urea (mmol/L)   2.3–8.9  5.6 (2.8–8.3)  7.4 (3.0–27.4)  566 
Glucose (mmol/L)    3.3–5.5  5.6 (5.1–6.8)  5.1 (0.3–9.8)  567 
Alanine aminotransferase (U/L)  9–73  35 (22–75)  30 (10–124) 568 
Alkaline phosphatase (U/L)   20–165  58 (16–229)  124 (23–631) 569 
Total bilirubin (µmol/L)   1–6.8  ND   8.6 (1.8–248.7)  570 
Inorganic phosphorus (mmol/L)  0.7–2.1  ND   1.43 (0.73–3.55) 571 














Table 2 584 
Results of routine renal biomarkers in healthy control dogs (n=10) and in dogs with babesiosis at presentation (n=35), 24 hours after 585 
presentation (n=11), and 1 month after treatment (n=9). All variables are expressed as median (range). 586 
Variable (unit) H  B T0  B T24h  B T1m  Pa Pb Pc Pd 587 
sCr (µmol/L) 82  63  67  76  0.093 0.18 0.57       0.54 588 
  (47–104)  (25–132)  (25–129)  (46–110) 589 
Serum urea 5.6  7.4      0.096 590 
(mmol/L)  (2.8–8.3)  (3.0–27.4) 591 
USG  1.039  1.042  1.032  1.023  0.13 0.057 0.008     0.39 592 
  (1.017–1.050) (1.015–>1.060) (1.022–1.045) (1.018–1.051)  593 
uOsmol  1254  1315   1062  927  0.45 0.15 0.098     0.35 594 
(mOsmol/kg) (579–2099) (430–2470) (683–1704) (676–2211) 595 
UPC  0.14  2.63  1.02  0.11  <0.001 0.002 0.016     0.56 596 
  (0.08–0.36) (0.34–15.42) (0.22–4.02) (0.07–0.29)   597 
H: healthy control dogs; B T0: dogs with babesiosis at presentation; B T24h: dogs with babesiosis 24 hours after presentation; B T1m: dogs 598 
with babesiosis 1 month after treatment; sCr: serum creatinine; USG: urine specific gravity; uOsmol: urine osmolality; UPC: urinary 599 
protein to creatinine ratio. 600 
aP values for the comparison between healthy control dogs and dogs with babesiosis at T0 601 
bP values for the comparison between dogs with babesiosis at T0 and T24h 602 
cP values for the comparison between dogs with babesiosis at T0 and T1m 603 













Table 3  615 
Kidney injury biomarkers and serum SDMA in healthy control dogs (n=10) and dogs with babesiosis at presentation (n=35), 24 hours 616 
after presentation (n=11), and 1 month after treatment (n=9). All variables are expressed as median (range). 617 
Variable (unit) H  B T0  B T24h  B T1m  Pa Pb Pc             Pd 618 
uIgG/uCr (mg/g) 1.93  435.43   190.68  1.29  <0.001 0.084 0.016     0.88 619 
  (0.55–11.32) (6.95–11544.30) (4.62–1362.46) (0.78–10.21) 620 
uCRP/uCr (mg/g) BDL (n=10) 0.13 (BDL–17.63) 0.14  BDL (n=10) <0.001 0.084 0.016       1.0 621 
                   BDL(n=2);BQL(n=2) (BDL(n=1)–0.43)   622 
uRBP/uCr (mg/g) 0.012 (BDL–0.034) 0.92 (0.26–7.71) 0.74 (0.020–1.16) BQL  <0.001 0.006 0.016     0.73 623 
  BDL(n=2);BQL(n=2)     (BQL(n=4)–0.32) 624 
uNGAL/uCr (µg/g) 0.76  377.57  246.82  0.30  <0.001 0.002 0.016     0.53 625 
  (0.21–7.08) (43.01–2645.43) (29.60–782.87) (0.08–28.06) 626 
pNGAL (ng/mL) 6.09  10.71  15.38  12.09   <0.001 0.12 0.30     0.028 627 
  (2.08–12.32) (5.95–121.77) (6.17–29.68) (3.52–15.41)  628 
u/pNGAL  0.21  54.77   31.82  0.28  <0.001 0.008 0.063     0.76 629 
  (0.024–3.40) (19.98–208.54) (1.98–68.13) (0.032–1.51) 630 
sSDMA (µg/dL) 14  14  17  12  0.68 0.88 0.078     0.12 631 
  (10–24)  (8–45)  (11–20)  (9–15)  632 
H, healthy control dogs; B T0, dogs with babesiosis at presentation; B T24h, dogs with babesiosis 24 hours after presentation; B T1m, dogs 633 
with babesiosis 1 month after treatment; uIgG, urinary immunoglobulin G; uCr, urinary creatinine; uCRP, urinary C-reactive protein; BDL, 634 
below detection limit; BQL, below quantification limit; uRBP, urinary retinol-binding protein; uNGAL, urinary neutrophil gelatinase-635 
associated lipocalin; pNGAL, plasma neutrophil gelatinase-associated lipocalin; u/pNGAL, urinary to plasma neutrophil gelatinase-636 
associated lipocalin ratio; sSDMA, serum symmetric dimethylarginine. 637 
aP values for the comparison between healthy control dogs and dogs with babesiosis at T0 638 
bP values for the comparison between dogs with babesiosis at T0 and T24h 639 
cP values for the comparison between dogs with babesiosis at T0 and T1m  640 









Table 4  648 
Results of routine renal biomarkers, kidney injury biomarkers, and serum SDMA in 10 dogs with uncomplicated and 25 dogs with 649 
complicated babesiosis at T0. All variables are expressed as median (range). 650 
Variable (unit)   Uncomplicated disease  Complicated disease  P value 651 
sCr (µmol/L)   53 (32–83)   70 (25–132)  0.27 652 
Serum urea (mmol/L)  4.8 (3.0–8.2)   8.6 (3.4–27.4)  0.007 653 
USG    1.045 (1.035–>1.060)  1.040 (1.015–>1.060) 0.30 654 
uOsmol (mOsmol/kg)  1509 (1199–2470)   1236 (430–2118)  0.054 655 
UPC    1.24 (0.34–3.79)   3.18 (0.51–15.42)  0.008  656 
uIgG/uCr (mg/g)   174.40 (6.95–3373.12)  705.53 (38.86–11544.30) 0.025 657 
uCRP/uCr (mg/g)   0.014 (BDL–1.07)   0.47 (BDL–17.63)  0.001 658 
    BDL (n=1); BQL (n=2)  BDL (n=1) 659 
uRBP/uCr (mg/g)   0.83 (0.29–2.07)   0.92 (0.26–7.71)  0.51 660 
uNGAL/uCr (µg/g)   322.32 (43.01–602.81)  401.38 (77.44–2645.43) 0.11 661 
pNGAL (ng/mL)   13.08 (7.46–31.25)   10.50 (5.95–121.77)  0.73 662 
u/pNGAL    55.23 (21.52–110.00)  50.99 (19.98–208.54) 0.90 663 
sSDMA (µg/dL)   13 (8–23)    17 (10–45)  0.038 664 
sCr: serum creatinine; USG: urine specific gravity; uOsmol: urine osmolality; UPC: urinary protein to creatinine ratio; uIgG: urinary 665 
immunoglobulin G; uCr: urinary creatinine; uCRP: urinary C-reactive protein; BDL: below detection limit; BQL: below quantification limit; 666 
uRBP: urinary retinol-binding protein; uNGAL: urinary neutrophil gelatinase-associated lipocalin; pNGAL: plasma neutrophil gelatinase-667 














Fig. 1. Kidney injury biomarkers (A: uIgG/uCr; B: uCRP/uCr; C: uRBP/uCr; D: uNGAL/uCr; E: pNGAL; F: u/pNGAL) and serum SDMA (G) 680 
in healthy control dogs (H, n=10) and dogs with babesiosis at presentation (B T0, n=35), 24 hours after presentation (B T24h, n=11), and 1 681 
month after treatment (B T1m, n=9). Data are presented as boxes and whiskers. Each box includes the interquartile range and the line within 682 
each box represents the median. The whiskers represent the range, extending to a maximum of 1.5 times the interquartile range. Outliers 683 
are not shown. *Significantly different (P<0.05) from healthy control dogs. ** Significantly different (P<0.05) from dogs with babesiosis at 684 
presentation. 685 
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